false
Catalog
2024 World Conference on Lung Cancer (WCLC) - ePos ...
EP.07E.04 Efficacy and Safety of Anlotinib Plus EG ...
EP.07E.04 Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs
Back to course
Pdf Summary
The study explored the effectiveness and safety of combining anlotinib, a multi-targeting tyrosine kinase inhibitor, with EGFR-TKIs in treating non-small cell lung cancer (NSCLC) patients who developed resistance to postoperative EGFR-TKIs. Anlotinib is known for its anti-tumor angiogenic properties and its ability to inhibit malignant tumor progression. The goal was to determine if this combination could extend the treatment window and improve survival rates for such patients.<br /><br />A total of 48 NSCLC patients, confirmed via cytological or histological tests, with specific EGFR mutations (Exon 19 deletion or L858R mutation), were enrolled. These patients had previously undergone surgery and adjuvant therapy with EGFR-TKIs but showed slow or local progression.<br /><br />The treatment involved administering anlotinib (10 mg, orally, on days 1-14 of a 21-day cycle) alongside continuing their original EGFR-TKI regimen until disease progression or treatment intolerance occurred.<br /><br />The results revealed a median progression-free survival (PFS) of 10.3 months for those previously treated with first- or second-generation EGFR-TKIs, and 7.7 months for those on third-generation EGFR-TKIs. The overall survival (OS) data was not reached for some groups, but was 20.3 months for others.<br /><br />Safety assessments showed that most adverse events (AEs) were mild or moderate, with hypertension (35.4%) and proteinuria (31.3%) being the most common. Only 8.3% required dose reduction, and 10.4% discontinued anlotinib due to AEs.<br /><br />The study concluded that the anlotinib and EGFR-TKI combination offered promising efficacy and manageable safety, extending treatment options and potentially improving outcomes for NSCLC patients with EGFR-positive mutations facing resistance issues.
Asset Subtitle
Jiayue Ye
Meta Tag
Speaker
Jiayue Ye
Topic
Early-Stage Non-small Cell Lung Cancer
Keywords
anlotinib
EGFR-TKIs
non-small cell lung cancer
NSCLC
tyrosine kinase inhibitor
EGFR mutations
progression-free survival
overall survival
adverse events
treatment resistance
×
Please select your language
1
English